Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

2014-08-27 03:19:49 | BioPortfolio


Dendritic cell therapy is a promising strategy for adjuvant cancer therapy in the setting of minimal residual disease (MRD) to fight off cancer relapse and/or progression. The investigators already performed a phase I safety study in leukemia patients that were in complete remission demonstrating the absence of side effects and feasibility of the therapy. Here, the investigators want to extend on this strategy by studying the clinical efficacy of autologous DC vaccination in patients with acute and chronic myeloid leukemia and myeloma patients. Effects of DC therapy on the immune reactivity towards leukemia cells as well as clinical parameters such molecular MRD monitoring, time to relapse (TTR), progression-free survival (PFS) and overall survival(OS) will be studied in vaccinated and non-vaccinated (control) patients. Patients will be vaccinated using their own dendritic cells electroporated with mRNA coding for the full-length Wilms' tumor antigen WT1.

Study Design

Endpoint Classification: Efficacy Study, Primary Purpose: Treatment


Acute Myeloid Leukemia


dendritic cell vaccination (active specific immunotherapy)


University Hospital Antwerp


Enrolling by invitation


University Hospital, Antwerp

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:19:49-0400

Clinical Trials [2782 Associated Clinical Trials listed on BioPortfolio]

Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission

RATIONALE: Vaccines made from a patient's white blood cells (dendritic cells) and a specific leukemia antigen (Wilms tumor antigen-1) may induce an effective immune response to kill residu...

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

1. Determine the feasibility of generation of autologous Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia in myeloid blast crisis (CML/BC) derived dendritic cell ...

Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma

The use of adjuvant vaccination with autologous dendritic cells (DC) matured in situ after being loaded with tumor lysates derived from autologous refractory sarcoma tissue will be safe, f...

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Vaccination of Patients With Stage IV Melanoma With Dendritic Cells

The purpose of this study is to test a novel dendritic cell (DC) vaccine in patients with Stage IV melanoma.

PubMed Articles [33991 Associated PubMed Articles listed on BioPortfolio]

Vaccination in the immunotherapy of glioblastoma.

Glioblastoma remains one of the most common central nervous system tumors with an extremely poor prognosis. Recently, rapid progress in immunotherapy has provided new options for the treatment of glio...

Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.

Glioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary ...

Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.

Combination immunotherapy has the potential to achieve additive or synergistic effects. Combined local injections of dsRNA analogues (mimicking viral RNA) and repeated vaccinations with tumor-lysate l...

Cutaneous presentation preceding acute myeloid leukemic with CD4+/CD56+ expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: a case report.

Acute myeloid leukemia (AML) may initially present as cutaneous lesions corresponding to blasts involving the skin as the first clinical manifestation prior to blood and bone marrow (BM) infiltration....

Dendritic cell immunotherapy followed by cART interruption during HIV-1 infection induces plasma protein markers of cellular immunity and neutrophil recruitment.

To characterize the host response to dendritic cell-based immunotherapy and subsequent combined antiretroviral therapy (cART) interruption in HIV-1-infected individuals at the plasma protein level.

Medical and Biotech [MESH] Definitions

A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

An extramedullary tumor of immature MYELOID CELLS or MYELOBLASTS. Granulocytic sarcoma usually occurs with or follows the onset of ACUTE MYELOID LEUKEMIA.

Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.

An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.

More From BioPortfolio on "Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Searches Linking to this Trial